Reimbursement

United States – October 17, 2026 -- Digital Diagnostics says its LumineticsCore system avoided 91% of unnecessary specialty visits in a pivotal clinical trial and cut time-to-follow-up for positive patients from 60 days to 5 days. The company made the claims in AdvaMed's "The Insight Series: AI & Digital Health," speaking through Jacque Engle, Vice President of Marketing & Communication, and Juli Goldstein, Vice President of Government Affairs & Market Access.

Washington – October 16, 2026 -- Nearly half of patients with hormone receptor positive, HER2 negative advanced breast cancer develop resistance to first-line endocrine therapy driven by the ESR1 mutation (ESR1m), according to a new Academy of Managed Care Pharmacy (AMCP) Market Insights Program report. The report finds that biomarker testing and treatment paradigms are evolving faster than the evidence payers need to manage them.

Testing uncertainty drives inconsistent practice and coverage friction

Patients with ESR1m stay on ineffective treatment until radiologic progression is detected. Monitoring for the mutation with circulating tumor DNA (ctDNA) liquid biopsy before progression can enable an early switch to effective therapy and extend time on first-line treatment.

Stockholm – October 14, 2026 -- SciBase Holding AB (STO: SCIB) has received its first positive medical policy for Nevisense from Highmark Blue Cross Blue Shield, which serves more than 7 million members across multiple US states. The decision moves eligible use of the skin-lesion device from a predominantly cash-pay model into covered care through a major private insurer.

Highmark policy applies to all commercial lines and opt-in self-funded groups

Highmark considers electrical impedance spectroscopy (EIS) medically necessary when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy. The procedure is reported under CPT code 0658T. The policy covers all Highmark commercial insured lines of business and self-funded (ASO) employer groups that elect it.

Coverage is limited to defined cases:

Burlington – October 12, 2026 -- Eighty-six percent of 21 heart failure patients at imminent risk of hospital admission were decongested at home without hospitalization using SQ Innovation's subcutaneous furosemide product Lasix ONYU, according to interim results from the investigator-sponsored Gator SCALES-WHF study.

Three patients were admitted within 30 days for additional treatment. The data were presented on October 11 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona.

University of Florida study tests same-day home treatment pathway

Gator SCALES-WHF is a prospective, open-label, single-arm, real-world study at the University of Florida in Gainesville. Principal Investigator Mustafa M. Ahmed, MD, leads the trial, and cardiology fellow Jude ElSaygh, MD, presented the interim data.